Why is mucormycosis more difficult to cure than more common mycoses?
暂无分享,去创建一个
[1] D. Kontoyiannis,et al. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. , 2013, Medical mycology.
[2] Kieren A Marr,et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. , 2012, The Journal of infection.
[3] B. Spellberg,et al. Pathogenesis of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] D. Kontoyiannis,et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] C. Elie,et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] D. Kontoyiannis,et al. Host defenses against zygomycetes. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] D. Kontoyiannis,et al. Epidemiology and clinical manifestations of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] B. Spellberg,et al. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] P. Hamal,et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] D. Kontoyiannis,et al. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Russell E. Lewis,et al. Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species , 2011, Clinical Microbiology Reviews.
[12] D. Kontoyiannis,et al. Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron , 2010, Antimicrobial Agents and Chemotherapy.
[13] T. Walsh,et al. Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. , 2010, Medical mycology.
[14] David W. Denning,et al. Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation , 2010, Journal of Clinical Microbiology.
[15] A. Simon,et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.
[16] D. Kontoyiannis,et al. Comparative Pharmacodynamics of Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Murine Model of Pulmonary Mucormycosis , 2009, Antimicrobial Agents and Chemotherapy.
[17] K. Gupta,et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. , 2009, The Journal of infectious diseases.
[18] D. Kontoyiannis,et al. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. , 2009, The Journal of infection.
[19] Ashraf S. Ibrahim,et al. Genomic Analysis of the Basal Lineage Fungus Rhizopus oryzae Reveals a Whole-Genome Duplication , 2009, PLoS genetics.
[20] B. Spellberg,et al. Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] E. Anaissie,et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] G. Samonis,et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. , 2009, The Journal of infectious diseases.
[23] D. Benjamin,et al. Zygomycosis in neonates: an uncommon but life-threatening infection. , 2009, American journal of perinatology.
[24] E. Dannaoui,et al. Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[25] T. Walsh,et al. Invasive zygomycosis in neonates and children. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[26] A. Francesconi,et al. Detection of a Molecular Biomarker for Zygomycetes by Quantitative PCR Assays of Plasma, Bronchoalveolar Lavage, and Lung Tissue in a Rabbit Model of Experimental Pulmonary Zygomycosis , 2008, Journal of Clinical Microbiology.
[27] D. Kontoyiannis,et al. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] O. Lortholary,et al. Molecular Diagnosis of Saksenaea vasiformis Cutaneous Infection after Scorpion Sting in an Immunocompetent Adolescent , 2008, Journal of Clinical Microbiology.
[29] G. Halder,et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis , 2008, Proceedings of the National Academy of Sciences.
[30] W. Steinbach,et al. Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases , 2008, Pediatrics.
[31] N. Gow,et al. Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.
[32] D. Stevens,et al. Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.
[33] D. Kontoyiannis,et al. Zygomycetes Hyphae Trigger an Early, Robust Proinflammatory Response in Human Polymorphonuclear Neutrophils through Toll-Like Receptor 2 Induction but Display Relative Resistance to Oxidative Damage , 2007, Antimicrobial Agents and Chemotherapy.
[34] S. Balajee,et al. DNA and the classical way: identification of medically important molds in the 21st century. , 2007, Medical Mycology.
[35] T. Walsh,et al. Zygomycosis in Children: A Systematic Review and Analysis of Reported Cases , 2007, The Pediatric infectious disease journal.
[36] D. Kontoyiannis,et al. Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis , 2007, Antimicrobial Agents and Chemotherapy.
[37] V. Sakhuja,et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. , 2006, Medical mycology.
[38] D. Loebenberg,et al. In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.
[39] M. Netea,et al. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[40] G. S. de Hoog,et al. Genetic Identification of the Main Opportunistic Mucorales by PCR-Restriction Fragment Length Polymorphism , 2006, Journal of Clinical Microbiology.
[41] F. Dromer,et al. Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues , 2006, Journal of Clinical Microbiology.
[42] P. Iwen,et al. Molecular Identification of Rhizomucor pusillus as a Cause of Sinus-Orbital Zygomycosis in a Patient with Acute Myelogenous Leukemia , 2005, Journal of Clinical Microbiology.
[43] M. Netea,et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. , 2005, Medical mycology.
[44] J. Collomb,et al. Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR-restriction fragment-length polymorphism method. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] D. Kontoyiannis,et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] Brad Spellberg,et al. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management , 2005, Clinical Microbiology Reviews.
[47] S. Shoham,et al. The immune response to fungal infections , 2005, British journal of haematology.
[48] Russell E. Lewis,et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.
[49] T. Walsh,et al. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. , 2005, The Journal of infectious diseases.
[50] B. Spellberg,et al. Caspofungin Inhibits Rhizopus oryzae 1,3-β-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis , 2005, Antimicrobial Agents and Chemotherapy.
[51] Y. Ohtsuki,et al. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae , 2004, Respirology.
[52] Robin Patel,et al. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[53] T J Walsh,et al. Infections due to emerging and uncommon medically important fungal pathogens. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[54] L. Pagano,et al. Mucormycosis in hematologic patients. , 2004, Haematologica.
[55] J. Meis,et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.
[56] J. Graybill,et al. In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes , 2002, Antimicrobial Agents and Chemotherapy.
[57] Lawrence Corey,et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] D. Kontoyiannis,et al. Zygomycosis in the 1990s in a tertiary-care cancer center. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] J. Ribes,et al. Zygomycetes in human disease. , 2000, Clinical microbiology reviews.
[60] W. Liles,et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. , 1997, The Journal of infectious diseases.
[61] Y. Schneider,et al. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. , 1994, Biochemical pharmacology.
[62] R. Crichton,et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. , 1994, Kidney international.
[63] Y. Schneider,et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. , 1993, The Journal of clinical investigation.
[64] J. V. van Cutsem,et al. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). , 1989, Kidney international.
[65] J. Perfect,et al. Disseminated zygomycosis: report of four cases and review. , 1989, Reviews of infectious diseases.
[66] C. de Vroey,et al. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. , 1988, Clinical nephrology.
[67] S. Levitz,et al. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. , 1984, The Journal of infectious diseases.
[68] Cowan Df,et al. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. , 1984 .